Genetic and Metabolism of Post-prandial HDL Particles (NCT03109067) | Clinical Trial Compass
CompletedNot Applicable
Genetic and Metabolism of Post-prandial HDL Particles
France100 participantsStarted 2011-09-21
Plain-language summary
Reverse cholesterol transport (RCT) pathway explains the anti-atherosclerosis role of HDL. Post prandial hypertriglyceridemia is highly predictive of atherosclerosis. TaqIB polymorphism in CETP gene plays a role on HDL particles, and might give a link between TaqIB polymorphism and the cardioprotective efficiency of HDL particles. Our main objective was to compare post-prandial HDL particles between patients having B2 allele carriers (genotype AA) to B1 allele carriers (genotype GG), and their ability to mediate cellular cholesterol efflux, via SR-BI Scavenger Receptor class B type I (SR-BI) , ABCG1 and ABCA1 pathways.
Who can participate
Age range18 Years – 60 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Affiliation to a national social security scheme
✓. Age between 18 and 60 years old
✓. Male subjects
✓. Participants harboring either a B2 (genotype AA) allele or a B1 (genotype GG) in TaqIB polymorphism of CETP gene
. Participants having a treatment (either systemic or local) which might interfere with the evaluation of study parameters.
✕. Excessive alcohol consumption, or any drug addiction. An excessive alcohol consumption is superior to 21 time 30 mL of alcohol or 120 mL of wine or 355 mL of beer.
✕. Regular smoker or smoking cessation within the last year
✕. Significant abnormality on the full blood count or plasmatic and urinary biochemistry analysis.
✕. Chronic or acute disease either life threatening or able to modify study results, including among others :